> Back to JHP Titles

COST-EFFICIENCY OF EMPLOYEE INFLUENZA VACCINATION: STRATEGIES TO MAXIMIZE EMPLOYER BENEFIT

Panel Leaders
Stephanie Cook, MD, The Ohio State University, Columbus, OH
Greg Poland, MD, Mayo Clinic and Foundation, Rochester, MN

Panel members (in alphabetical order)
William Bunn III, MD, International Truck and Engine Company, Warrenville, IL
Jessica Herzstein, MD, Air Products and Chemicals Inc., Allentown, PA
Arnold Monto, MD, University of Michigan, School of Public Health, Ann Arbor, MI
Brent Pawlecki, MD, Pitney Bowes Inc., Stamford, CT
Dan Pikelny, MA, MBA, International Truck and Engine Company, Warrenville, IL

1. Department of Health and Human Services. Centers for Disease Control and Prevention. Influenza (flu). Aug 30, 2006; www.cdc.gov/flu. Accessed April 2, 2006.

2. Szucs T. The socio-economic burden of influenza. J Antimicrob Chemother. Nov 1999;44 Suppl B. US costs for 1999 adapted from: The Office of Technology Assessment. US Congress. Cost-Effectiveness of Influenza Vaccination. 1981.Government Printing Office, Washington, DC. Document No. 052-00-003-00855-6:11-15.

3. Morbidity and Mortality Weekly Report. Recommendations and Reports. Prevention and Control of Influenza. Recommendations of the ACIP. 2006;55. No. RR-10.

4. Strikas RA, Wallace GS, Myers MG. Influenza pandemic preparedness action plan for the United States: 2002 update. Clin Infect Dis. Sep 1 2002;35:590-596.

5. Meltzer MI, Cox NJ, Fukuda K. The economic impact of pandemic influenza in the United States: priorities for intervention. Emerg Infect Dis. Sep-Oct 1999;5(5):659-671.

6. The Congress of the United States. Congressional Budget Office. A potential influenza pandemic: possible macroeconomic effects and policy issues. 2006.

7. Homeland Security Council. Chapter 2. US Government Planning for a Pandemic. Implementation Plan for the National Strategy for Pandemic Influenza. 2006

8. US Department of Labor. Occupational Safety and Health Administration. Guidance on Preparing Workplaces for an Influenza Pandemic. 2007.

9. World Health Organization. Guidelines for the use of seasonal influenza vaccine in humans at risk of H5N1 infection. 2004.

10. 2006 National Influenza Vaccine Summit (Sponsored by the American Medical Association and the Centers for Disease Control and Prevention). Atlanta, GA 2006.

11. Talbot E, Brown K, Kirkland K, et al. Safety of mass immunization with tetanusdiphtheria-acellular pertussis vaccine (Tdap) during a NH hospital pertussis outbreak. Annual Meeting of the Infectious Diseases Society of America; 2006.

12. Centers for Disease Control. Best Practices for Mass Influenza Vaccination Campaigns. Accessed April 30, 2007.

13. Keech M, Scott AJ, Ryan PJ. The impact of influenza and influenza-like illness on productivity and healthcare resource utilization in a working population. Occup Med (Lond). Feb 1998;48(2):85-90.

14. Adams PF, Hendershot GE, Marano MA. Current estimates from the National Health Interview Survey, 1996. Vital Health Stat 10. Oct 1999(200):1-203.

15. Singh S, Barghoorn J, Bagdonas A, et al. Clinical Benefits With Oseltamivir in Treating Influenza in Adult Populations: Results of a Pooled and Subgroup Analysis. Clin Drug Invest. 2003;23:561-569.

16. Goetzel RZ, Hawkins K, Ozminkowski RJ, Wang S. The health and productivity cost burden of the "top 10" physical and mental health conditions affecting six large U.S. employers in 1999. J Occup Environ Med. Jan 2003;45(1):5-14.

17. Stewart WFM, D. Verdon, C. The american productivity audit and the campaign for work and health.: The Center for Work and Health, Advance PCS; 2003.

18. New national survey shows employees feel pressured to go to work, despite being: Omnibus survey. CARAVAN Opinion Research Corporation. NFID Press Release: Feb. 27, 2006; 2006.

19. Centers for Disease Control. Questions and Answers: the Nasal-Spray Flu Vaccine (Live Attenuated Influenza Vaccine [LAIV]). October 2006; http://www.cdc.gov/flu/about/qa/nasalspray.htm. Accessed April 23, 2007.

20. 2006-2007 Infleunza Prevention and Control Recommendations: Efficacy and Effectiveness of Inactivated Influenza Vaccine. Sept. 8, 2006; www.cdc.gov/flu/professionals/vaccination/efficacy.htm. Accessed Nov 18, 2006.

21. Bridges CB, Thompson WW, Meltzer MI, et al. Effectiveness and cost-benefit of influenza vaccination of healthy working adults: A randomized controlled trial. Jama. Oct 4 2000;284(13):1655-1663.

22. Nichol K, Lind A, Margolis K, et al. The effectiveness of vaccination against influenza in healthy, working adults. New England Journal of Medicine. 1995;333:889-893.

23. Centers for Disease Control and Prevention. Questions and Answers: Flu Shot. July 2006; http://www.cdc.gov/flu/about/qa/flushot.htm. Accessed April 23, 2007.

24. Nichol KL. Cost-benefit analysis of a strategy to vaccinate healthy working adults against influenza. Arch Intern Med. Mar 12 2001;161(5):749-759.

25. Nichol KL, Mallon KP, Mendelman PM. Cost benefit of influenza vaccination in healthy, working adults: an economic analysis based on the results of a clinical trial of trivalent live attenuated influenza virus vaccine. Vaccine. May 16 2003;21(17-18):2207-2217.

26. Centers for Disease Control. National Immunization Program: Vaccine Price List. 2007; http://www.cdc.gov/nip/vfc/cdc_vac_price_list.htm#top. Accessed April 23, 2007.

27. Consumer Price Index (CPI) Inflation Calculator. http://data.bls.gov/cgi-bin/cpicalc.pl. Accessed April 23, 2007.

28. Burckel E, Ashraf T, de Sousa Filho JP, et al. Economic impact of providing workplace influenza vaccination. A model and case study application at a Brazilian pharma-chemical company. Pharmacoeconomics. Nov 1999;16(5 Pt 2):563-576.

29. Samad AH, Usul MH, Zakaria D, et al. Workplace vaccination against influenza in Malaysia: does the employer benefit? J Occup Health. Jan 2006;48(1):1-10.

30. Saxen H, Virtanen M. Randomized, placebo-controlled double blind study on the efficacy of influenza immunization on absenteeism of health care workers. Pediatr Infect Dis J. Sep 1999;18(9):779-783.

31. Data from Employer Advisory Boards Sponsored by Novartis Vaccines. 2007.

32. National Foundation for Infectious Diseases. Nation's Top Health Experts Urge Influenza and Pneumococcal Vaccination as Influenza Season Approaches. Washington, DC September 14 2005.

33. Poland G, Couch R. Intranasal influenza vaccine. Adding to the armamentarium for influenza control. Journal of American Medical Association. 1999;281:182-183.

34. Poland GA, Tosh P, Jacobson RM. Requiring influenza vaccination for health care workers: seven truths we must accept. Vaccine. Mar 18 2005;23(17-18):2251-2255.

35. Department of Health and Human Services. Centers for Disease Control and Prevention. National Immunization Program. ACIP. Atlanta, Georgia June 29-30 2006.

36. World Health Organization. Global pandemic influenza action plan to increase vaccine supply. 2006.

37. Centers for Disease Control. Questions and Answers About Avian Influenza (Bird Flu) and Avian Influenza A (H5N1) Virus. 2007. Accessed April 23, 2007.

38. Sandbulte MR, Jimenez GS, Boon AC, Smith LR, Treanor JJ, Webby RJ. Cross-Reactive Neuraminidase Antibodies Afford Partial Protection against H5N1 in Mice and Are Present in Unexposed Humans. PLoS Med. Feb 13 2007;4(2):e59.